OncoSec Medical Inc (ONCSQ)

[lasers]

$ONCS PFS Results 57% at 18 months

Stage IIIb and IIIc 14 (60.9%)

Stage IV M1a and M1b 4 (17.4%)

Stage IV M1c 5 (21.7%)

http://oncosec.com/wp-content/uploads/2017/11/ONCS-SITC-POSTER-2017_-1.pdf

This trial was designed By Merck, UCSF and $ONCS

Total nonsense your statement:

It appears to me ONCS is fooling retail investors or anyway investors not expert of melanoma and cancer in general,

PFS Results 57% at 18 months P524 SITC

Progression free survival (PFS) rates for this
treatment were 62% at 6 months and 57% at 18
months (median PFS not reached at 24 months)
with a 48% BORR. DOR was not assessable as no
responders have progressed and no safety signals
were observed with only 2/22 grade 3 treatment-
emergent adverse events. In responding patients,
significant post-treatment increases were observed
in both the Th1-associated gene expression of
STAT4 and IL-12RB in biopsies, and frequencies of
CD8+
PD-1+
TIGIT+ and proliferating CD8+
PD-1+
peripherally. Additionally, responding patients had a
significant increase of TCR clonality in the tumors
compared to PBMCs with a reversed relationship in
non-responding patients. Spatial analysis by mIHC
revealed a significant increase of both PD-L1+ and
FoxP3+ cells <15um from CD8+ T cells in non-
responders. Exploratory analysis with Nanostring’s
IO360 Beta Version panels highlighted
underexpression of WNT2B and overexpression of
MICB in the pretreatment responder biopsies.
Conclusions
Durable responses and favorable PFS rates in likely
PD-1 non responders continues to suggest that
combination IT-TAVO-EP with pembrolizumab is an
effective therapeutic modality with an excellent
safety profile. Associated biomarker data highlights
connected immunological mechanisms, whereby
intratumoral Th1-polarization, associated TCR
clonality and limited suppressive cell types can drive
robust anti-tumor responses (intratumoral and
systemic) that positively impact this difficult to treat
patient population.